Sana Biotechnology (NASDAQ:SANA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a sell rating to a hold rating in a research note issued to investors on Saturday.

SANA has been the topic of a number of other research reports. Citizens Jmp upped their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sana Biotechnology in a report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. Wedbush raised their target price on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, HC Wainwright cut their target price on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Trading Down 3.1%

NASDAQ SANA opened at $4.36 on Friday. The company has a fifty day simple moving average of $4.54 and a 200 day simple moving average of $3.84. Sana Biotechnology has a 12-month low of $1.26 and a 12-month high of $7.30. The company has a market cap of $1.16 billion, a P/E ratio of -4.49 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. Sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Trading of Sana Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its position in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after purchasing an additional 9,501 shares during the last quarter. Hoey Investments Inc. bought a new stake in shares of Sana Biotechnology during the 2nd quarter worth $33,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Sana Biotechnology during the 3rd quarter worth $36,000. TD Waterhouse Canada Inc. purchased a new position in shares of Sana Biotechnology in the 3rd quarter worth about $37,000. Finally, Lyell Wealth Management LP bought a new position in Sana Biotechnology during the third quarter valued at about $37,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.